Brind.

EMA adopted a positive opinion and the European Commission granted marketing authorization for the drug Hopledo.

1 report, 1 independent Updated Aug 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

European Medicines Agency European Commission Zambon

Keep exploring

The entities involved

European Medicines Agency
highest regulatory authority on medicines in the European Union
- Menarini Group and NewAmsterdam Pharma Company N.V. are collaborating on drug development, seeking marketing authorization in Europe through the EMA and EC process.Wed 15:03
- EMA adopted a negative opinion on MAA for Omeros Corporation, while Pomerantz LLP confirmed its global office locations.Tue 01:26
European Commission
executive branch of the European Union
- Romania is handing over the Central European Initiative (CEI) presidency, with Ukraine set to assume the role in 2027.01:21
- EU ministers met in Ireland to lobby for Kyiv's air defense needs, while Kyiv seeks US-made Patriot interceptors amid Russian attacks.Fri 23:37
Zambon
company in Barcelona, Spain

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 28finanznachrichten.de